Search

Displaying results 821 - 830 of 3180 in total
  1. Drug

    PF-477736

    go.drugbank.com/drugs/DB12611
    Investigational

    PF-00477736 has been used in trials studying the treatment of Neoplasms.

  2. Drug

    PF-04217903

    go.drugbank.com/drugs/DB12848
    Investigational

    PF-04217903 has been used in trials studying the treatment of Neoplasms.

  3. Drug

    PI-103

    go.drugbank.com/drugs/DB17046
    Experimental

    PI-103 is an inhibitor of p110α of class I PI3K.[A253092]

  4. Drug

    Dienogest

    go.drugbank.com/drugs/DB09123
    ApprovedInvestigational

    Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive i...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    PF-06273340

    go.drugbank.com/drugs/DB12269
    Investigational

    Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects

  6. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and progestogenic properties.

  7. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  8. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    Sulopenem etzadroxil is a prodrug of the penem antibacterial sulopenem. Like other beta-lactam antibacterials, it is a time-dependent inhibitor of bacterial cell wall synthesis. Sulopenem etzadroxil was approved by the FDA in October 202...

  9. Drug

    PF-03814735

    go.drugbank.com/drugs/DB13059
    Investigational

    PF-03814735 has been used in trials studying the treatment of Solid Tumors.

  10. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates